Business Context and Reporting Period
Company: American Shared Hospital Services (ASHS)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2014
Business Overview: ASHS provides Gamma Knife and radiation therapy services through a network of medical centers. As of June 30, 2014, the company operated 17 Gamma Knife units in the United States. The company also holds investments in Mevion Medical Systems (proton beam therapy) and recently divested its Turkish subsidiary, EWRS Turkey.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2014 | Six Months Ended June 30, 2013 |
|---|---|---|
| Medical Services Revenue | $7,443,000 | $9,251,000 |
| Gross Margin | $2,134,000 (28.7%) | $4,011,000 (43.4%) |
| Operating Loss | $(705,000) | $696,000 (Income) |
| Net Loss | $(1,105,000) | $130,000 (Income) |
| Net Loss Attributable to ASHS | $(1,023,000) | $(97,000) |
| Net Cash from Operating Activities | $2,392,000 | $3,591,000 |
| Cash and Cash Equivalents (End of Period) | $944,000 | $1,345,000 |
| Total Debt (Current + Long-Term) | $18,390,000 | $24,544,000 |
| Working Capital | $(2,222,000) | $(4,079,000) |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by 19.5% ($1.8M) year-over-year. This was driven by lower procedure volumes at existing sites, the sale of the EWRS Turkey subsidiary, and a shift in payor mix.
- Profitability Shift: The company reported a net loss of $1.1M for the six months ended June 30, 2014, compared to a net income of $130,000 in the prior year. The loss was primarily due to a $572,000 loss on the sale of EWRS Turkey and reduced operating income.
- Foreign Currency Impact: The company recorded a foreign currency gain of $161,000 for the six months ended June 30, 2014, reversing a loss of $534,000 in the prior year. This was largely due to the sale of the Turkish operation and the release of cumulative translation adjustments.
- Debt Reduction: Total debt obligations decreased significantly from $24.5M to $18.4M, largely due to proceeds from the sale of EWRS Turkey being used to pay down associated debt.
Guidance, Outlook, and Risks
- Divestiture: The company sold its Turkish subsidiary (EWRS Turkey) on June 10, 2014, for EUR 4.2 million. Proceeds were used to reduce debt, with $768,000 in excess cash retained. The company is eligible for future earn-outs based on revenue from the sold units.
- Expansion Commitments: ASHS has total remaining equipment purchase commitments of approximately $47 million, including three Mevion proton beam therapy systems and several Gamma Knife units. Approximately $35 million of these commitments are not due until 2016.
- Liquidity and Financing: The company has a $9 million line of credit with Bank of America, with $7.71 million drawn as of June 30, 2014. The facility was originally set to mature in 2014 but was extended to December 31, 2014, following a waiver of a profitability covenant default. Management believes cash flow from operations is adequate for the next 12 months.
- Investment Risk: The company holds a $2.7 million investment in Mevion Medical Systems. Management estimates an unrealized impairment of approximately $2.4 million but considers it temporary, citing Mevion's revenue backlog and successful clinical operations.
- Operational Outlook: Gamma Knife revenues improved in July 2014 compared to Q1 and Q2 2014 averages. However, the company faces challenges in obtaining financing for new projects due to current credit market conditions.
Key Facts for Investor Verification
- Debt Covenant Compliance: Verify the status of the profitability covenant waiver with Bank of America and the company's ability to meet the December 31, 2014 maturity date.
- Financing for Commitments: Confirm the company's ability to secure financing for the $47 million in equipment commitments, particularly for the Mevion proton beam systems.
- Mevion Investment Valuation: Monitor the financial health of Mevion Medical Systems to assess the potential for the $2.4 million impairment to become permanent.
- Revenue Recovery: Track procedure volumes and reimbursement rates at domestic Gamma Knife sites to confirm the sustainability of the revenue improvement noted in July 2014.
- Working Capital: Review the negative working capital position of $2.2 million and the company's liquidity management strategies.